Central Nervous System Effects Study Type: fMRI brain imaging study Key Finding: Cagrilintide activates amylin receptor-rich regions in the area postrema and nucleus tractus solitarius, distinct from GLP-1R activation patterns
A rigorous 2026 UK review covering the November 2025 FDA approval of Caplyta (lumateperone) for major depressive Read the full review Psychiatry & Cognitive Health 19 May 2026 Dihexa for Schizophrenia: KarXT/Cobenfy, Iclepertin CONNEX Failure, BDNF, C4 Pruning & the 2026 UK Review Can Dihexa help schizophrenia, cognitive impairment associated with schizophrenia (CIAS) or negative symptoms
Not well supported: High-quality, reproducible human trials demonstrating meaningful improvement in tendon/ligament healing time, re-injury rates, or function with these specific compoundsespecially as used in the wild (variable dosing, variable sourcing, variable diagnosis)
This gene-regulatory profile has made GHK-Cu skin research a particularly active field